-
公开(公告)号：EP3204384A1
公开(公告)日：2017-08-16
申请号：EP15848319.8
申请日：2015-10-08
发明人： UJJAINWALLA, Fez , TAN, John Qiang , DANG, Qun , SINZ, Christopher J. , WANG, Ming , CAI, Jiaqiang , DU, Xiaoxing , CHEN, Yili
IPC分类号： C07D471/20 , C07D401/14 , C07D471/04
CPC分类号： C07D213/82 , A61P7/08 , C07D401/04
摘要： The present invention concerns compounds of formula I that inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
摘要翻译： 本发明涉及抑制HIF脯氨酰羟化酶的式I化合物，它们用于增强促红细胞生成素的内源性产生的用途，以及用于治疗与促红细胞生成素的内源性产生减少有关的疾病如贫血等疾病的药物组合物以及包含这种化合物 和药物载体。
-
公开(公告)号：EP2970119A1
公开(公告)日：2016-01-20
申请号：EP14763846.4
申请日：2014-03-10
发明人： ACTON, John J, III , ANAND, Rajan , ARASAPPAN, Ashok , DANG, Qun , SEBHAT, Iyassu , PU, Zhifa , SUZUKI, Takao
IPC分类号： C07D209/12 , C07D209/30 , C07D403/10 , C07D471/04 , C07D487/04 , A61K31/404 , A61K31/4353 , A61K31/495 , A61K31/41 , A61K31/5365 , A61P3/10
CPC分类号： C07D471/04 , A61K31/366 , A61K31/397 , A61K31/404 , A61K31/437 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/4985 , A61K31/5377 , A61K31/541 , C07D209/08 , C07D209/12 , C07D209/18 , C07D209/30 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D405/04 , C07D405/06 , C07D405/10 , C07D413/04 , C07D413/10 , C07D493/04 , C07D519/00 , A61K2300/00
摘要： Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
摘要翻译： 结构式（I）的新型化合物是AMP-蛋白激酶的活化剂，可用于治疗，预防和抑制由AMPK激活的蛋白激酶介导的疾病。 本发明的化合物可用于治疗2型糖尿病，高血糖症，代谢综合征，肥胖症，高胆固醇血症和高血压。
-
13.发明公开TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C 审中-公开四环杂环化合物及其用于治疗丙型肝炎的方法
公开(公告)号：EP2953461A1
公开(公告)日：2015-12-16
申请号：EP14749562.6
申请日：2014-02-03
发明人： DAI, Xing , LIU, Hong , PALANI, Anandan , HE, Shuwen , LAI, Zhong , NARGUND, Ravi , MARCANTONIO, Karen , XIAO, Dong , BROCKUNIER, Linda, L. , ZORN, Nicolas , DANG, Qun , PENG, Xuanjia , LI, Peng
摘要： The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. I
摘要翻译： 本发明涉及可用作丙型肝炎病毒（HCV）NS5B聚合酶抑制剂，这类化合物的合成，以及这些化合物用于抑制HCV NS5B聚合酶活性，用于治疗或预防HCV感染的用途的式I化合物和 在基于细胞的系统中抑制HCV病毒复制和/或病毒产生。 一世
-
公开(公告)号：EP2875024A1
公开(公告)日：2015-05-27
申请号：EP13819609.2
申请日：2013-07-16
发明人： COLEMAN, Paul, J. , WALJI, Abbas , DANG, Qun , BENNETT, David, J. , CLAS, Sophie, D. , WAI, John , BALSELLS-PADROS, Jaume , WU, Henry, Y. , SMITH, Ronald, L. , NOFSINGER, Rebecca , SANCHEZ, Rosa, I.
IPC分类号： C07D413/12 , A61P31/18 , A61K31/506
CPC分类号： C07D413/12 , A61K31/427 , A61K31/513 , A61K31/52 , A61K45/06 , A61K2300/00
摘要： The present invention relates to Amido-Substituted Pyrimidinone Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein R
1 , R
2 , R
3 , R
4 , R
5 and R
6 are as defined herein. The present invention also relates to compositions comprising at least one Amido-Substituted Pyrimidinone Derivative, and methods of using the Amido-Substituted Pyrimidinone Derivatives for treating or preventing HIV infection in a subject.摘要翻译： 本发明涉及式（I）的酰氨基取代的嘧啶酮衍生物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5和R 6如本文所定义。 本发明还涉及包含至少一种酰胺取代的嘧啶酮衍生物的组合物，以及使用该酰胺取代的嘧啶酮衍生物治疗或预防受试者HIV感染的方法。
-
公开(公告)号：EP3924343A1
公开(公告)日：2021-12-22
申请号：EP09792782.6
申请日：2009-09-21
发明人： BOOKSER, Brett, C. , DANG, Qun , GIBSON, Tony, S. , JIANG, Hongjian , CHUNG, De Michael , BAO, Jianming , JIANG, Jinlong , KASSICK, Andy , KEKEC, Ahmet , LAN, Ping , LU, Huagang , MAKARA, Gergely, M. , ROMERO, F. Anthony , SEBHAT, Iyassu , WILSON, David , WODKA, Dariusz
IPC分类号： C07D235/26 , C07D235/28 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , A61K31/4184 , A61K31/4439 , A61P3/10
-
公开(公告)号：EP2758059B1
公开(公告)日：2018-10-24
申请号：EP12834521.2
申请日：2012-09-19
发明人： DANG, Qun , ZHOU, Changyou , ZOU, Wuxin , HUA, Yuxia
IPC分类号： A61K31/50 , A61K31/4965 , A01N43/54 , C07F9/6558
CPC分类号： C07F9/65583 , A61K31/505 , C07D413/14 , C07F9/65031 , C07F9/6521 , C07F9/65312
摘要： The present invention relates to substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
-
17.发明授权
公开(公告)号：EP2697242B1
公开(公告)日：2018-10-03
申请号：EP12771707.2
申请日：2012-04-11
发明人： GIRIJAVALLABHAN, Vinay , NJOROGE, F. George , BOGEN, Stephane , BENNETT, Frank , VERMA, Vishal , ARASAPPAN, Ashok , CHEN, Kevin , HUANG, Ying , KEREKES, Angela , NAIR, Latha , PISSARNITSKI, Dmitri , DANG, Qun , DAVIES, Ian , OLSEN, David, B. , STAMFORD, Andrew , VACCA, Joseph, P.
IPC分类号： C07H21/02 , C07H19/10 , C07H19/06 , C07H19/11 , C07H19/12 , C07H19/16 , C07H19/20 , C07H19/207 , C07H19/213 , A61K45/06 , A61K31/7056 , A61K31/706 , A61K31/7064 , A61K31/7072 , A61K31/708 , A61K31/7068 , A61P31/14
CPC分类号： C07H19/06 , A61K31/7056 , A61K31/706 , A61K31/7064 , A61K31/7068 , A61K31/7072 , A61K31/708 , A61K45/06 , A61P31/14 , C07H19/10 , C07H19/11 , C07H19/12 , C07H19/16 , C07H19/20 , C07H19/207 , C07H19/213
摘要： The present invention relates to 2′-Azido Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one 2′-Azido Substituted Nucleoside Derivative, and methods of using the 2′-Azido Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.
-
18.发明授权
公开(公告)号：EP2696681B1
公开(公告)日：2018-10-03
申请号：EP12771566.2
申请日：2012-04-11
发明人： GIRJAVALLABHAN, Vinay , NJOROGE, F. George , BOGEN, Stephane , VERMA, Vishal , BENNETT, Frank , KEREKES, Angela , ARASAPPAN, Ashok , PISSARNITSKI, Dimitri , DANG, Qun , DAVIES, Ian , OLSEN, David, B. , STAMFORD, Andrew , VACCA, Joseph, P.
IPC分类号： A61P31/14 , C07H21/02 , C07H19/10 , C07H19/06 , C07H19/11 , C07H19/12 , C07H19/16 , C07H19/20 , C07H19/207 , C07H19/213 , A61K31/7042 , A61K45/06 , A01N47/36 , A61K31/7068 , A61K31/7072
CPC分类号： A61K31/7072 , A01N47/36 , A61K31/7042 , A61K31/7068 , A61K45/06 , A61P31/14 , C07H17/02 , C07H19/10 , C07H19/11 , C07H19/207 , C07H19/213 , A01N2300/00 , A01N43/54 , A01N43/56 , A01N43/653 , A01N43/76 , A01N43/82 , A01N43/84 , A01N43/90
摘要： The present invention relates to 2′-Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, X, R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one 2′-Substituted Nucleoside Derivative, and methods of using the 2′-Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.
-
公开(公告)号：EP2560655B1
公开(公告)日：2016-08-24
申请号：EP11772489.8
申请日：2011-04-18
发明人： ZHOU, Changyou , ZOU, Wuxin , HUA, Yuxia , DANG, Qun
IPC分类号： A61K31/505 , C07D237/00 , A61P7/06
CPC分类号： C07D403/04 , C07D401/14 , C07D403/14 , C07D405/14
-
20.发明公开2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES 审中-公开2'-氰基取代FOR USE核苷及其方法进行病毒疾病治疗
公开(公告)号：EP2909209A1
公开(公告)日：2015-08-26
申请号：EP13846498.7
申请日：2013-10-11
IPC分类号： C07D487/04 , A61K31/5025 , A61P31/12
CPC分类号： C07D487/04 , A61K31/7056 , A61K31/706 , A61K38/212 , A61K45/06 , A61K47/48215 , A61K47/60 , C07F9/65616 , C07F9/65744 , A61K2300/00
摘要： Compounds of Formula (I) are disclosed, wherein R
1 , R
2 , R
3 , R
4 , R
5 , and R
18 are defined herein. The compounds encompassed by Formula (I) include compounds which are HCV NS5B inhibitors and other compounds which can be metabolized
in vivo to HCV NS5B inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HCV and the prophylaxis, treatment, or delay in the onset of disease caused by HCV. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
-
-
-
-
-
-
-
-
-
搜索结果
45 条记录 (耗时 0.025 秒)
